- Home
- IMUX vs SGA Comparison
IMUX vs SGA Comparison
Compare IMUX & SGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- SGA
- Stock Information
- Founded
- IMUX 2016
- SGA 1986
- Country
- IMUX United States
- SGA United States
- Employees
- IMUX N/A
- SGA N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- SGA Broadcasting
- Sector
- IMUX Health Care
- SGA Consumer Discretionary
- Exchange
- IMUX Nasdaq
- SGA Nasdaq
- Market Cap
- IMUX 100.0M
- SGA 74.4M
- IPO Year
- IMUX N/A
- SGA 1992
- Fundamental
- Price
- IMUX $1.07
- SGA $11.89
- Analyst Decision
- IMUX Strong Buy
- SGA
- Analyst Count
- IMUX 6
- SGA 0
- Target Price
- IMUX $12.67
- SGA N/A
- AVG Volume (30 Days)
- IMUX 885.0K
- SGA 42.0K
- Earning Date
- IMUX 02-20-2025
- SGA 11-07-2024
- Dividend Yield
- IMUX N/A
- SGA 8.41%
- EPS Growth
- IMUX N/A
- SGA N/A
- EPS
- IMUX N/A
- SGA 0.75
- Revenue
- IMUX N/A
- SGA $110,669,000.00
- Revenue This Year
- IMUX N/A
- SGA N/A
- Revenue Next Year
- IMUX N/A
- SGA $2.95
- P/E Ratio
- IMUX N/A
- SGA $15.84
- Revenue Growth
- IMUX N/A
- SGA N/A
- 52 Week Low
- IMUX $0.97
- SGA $10.75
- 52 Week High
- IMUX $2.11
- SGA $24.70
- Technical
- Relative Strength Index (RSI)
- IMUX 45.08
- SGA 48.60
- Support Level
- IMUX $0.99
- SGA $10.75
- Resistance Level
- IMUX $1.09
- SGA $11.89
- Average True Range (ATR)
- IMUX 0.06
- SGA 0.43
- MACD
- IMUX -0.00
- SGA 0.01
- Stochastic Oscillator
- IMUX 39.89
- SGA 48.10
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets and It derives a majority of its revenue from the sale of advertising for broadcast on its stations.